Preliminary results from a phase II study of lenalidomide monotherapy in Relapsed/Refractory aggressive non-Hodgkin's lymphoma.

被引：0
|
作者：
Wiemik, Peter H.
Lossos, Izidore
Tuscano, Joseph
Justice, Glen
Vose, Julie M.
Pietronigro, Dennis
Takeshita, Kenichi
Ervin-Haynes, Annette
Zeldis, Jerome B.
Habermann, Thomas M.
机构：
[1] Coll Med, Our Lady Canc Ctr, Bronx, NY 33152 USA
[2] Univ Miami, Sylvester Canc Ctr, Miami, FL 95817 USA
[3] Univ Calif Davis, Ctr Canc, Sacramento, CA USA
[4] Oncol Med Grp, Fountain Valley, CA 68182 USA
[5] Univ Nebraska, Omaha, NE USA
[6] Celgene Corp, Summit, NJ USA
[7] Mayo Clin, Rochester, MN USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
531
引用
收藏
页码：160A / 161A
页数：2
相关论文
共 50 条
  • [31] Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma
    Prichard, Mark
    Harris, Thomas
    Williams, Michael E.
    Densmore, John J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (06) : 983 - 995
  • [32] Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma
    Gillian M. Keating
    Drugs, 2016, 76 : 1579 - 1586
  • [33] Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma
    Weidmann, E
    Kim, SZ
    Rost, A
    Schuppert, H
    Seipelt, G
    Hoelzer, D
    Mitrou, PS
    ANNALS OF ONCOLOGY, 2002, 13 (08) : 1285 - 1289
  • [34] Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001
    Witzig, T. E.
    Wiernik, P. H.
    Moore, T.
    Reeder, C.
    Cole, C.
    Justice, G.
    Kaplan, H.
    Voralia, M.
    Pietronigro, D.
    Vose, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
    Witzig, T. E.
    Vose, J. M.
    Zinzani, P. L.
    Reeder, C. B.
    Buckstein, R.
    Polikoff, J. A.
    Bouabdallah, R.
    Haioun, C.
    Tilly, H.
    Guo, P.
    Pietronigro, D.
    Ervin-Haynes, A. L.
    Czuczman, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 (07) : 1622 - 1627
  • [36] Cologne high-dose sequential chemotherapy in relapsed and refractory aggressive non-Hodgkin's lymphoma results of multicenter phase II study
    Josting, A
    Sieniawski, M
    Staak, J
    Diehl, V
    Engert, A
    ANNALS OF ONCOLOGY, 2005, 16 : 183 - 183
  • [37] Phase II trial of Doxil® in patients with refractory/relapsed low-grade non-Hodgkin's lymphoma.
    Di Bella, NJ
    Khan, MM
    Dakhil, SR
    Logie, KW
    Marsland, TA
    Simon, SR
    Weinstein, RE
    BLOOD, 2000, 96 (11) : 236B - 236B
  • [38] Final results of the phase II trial of paclitaxel plus oral estramustine phosphate in patients with relapsed aggressive non-Hodgkin's Lymphoma.
    Borghaei, H
    Millenson, MM
    Schilder, RJ
    Rogatko, A
    Alden, M
    Wang, H
    Padavic-Shaller, KA
    Minnitti, C
    Smith, MR
    BLOOD, 2003, 102 (11) : 293B - 293B
  • [39] Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
    Keating, Gillian M.
    DRUGS, 2016, 76 (16) : 1579 - 1586
  • [40] Phase I/II Study of Dasatinib In Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    William, Basem M.
    Hohenstein, Maribeth
    Loberiza, Fausto R., Jr.
    Caponetti, Gabriel C.
    Bociek, R. Gregory
    Bierman, Philip
    Armitage, James O.
    Chan, Wing-Chung
    Vose, Julie M.
    BLOOD, 2010, 116 (21) : 131 - 131
12345